Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AMO Pharma LTD logo — AMO Pharma is working to develop novel therapeutics for rare...

AMO Pharma LTD

AMO Pharma is working to develop novel therapeutics for rare genetic neurodevelopmental disorders

Founded 2015 United States Durham, United States 12 employees Series A Total: $25.00M Biotechnology, Health Care +1

General Information

Company Name AMO Pharma LTD
Founded Year 2015
Location United States Durham, United States
Employees 12
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with AMO Pharma LTD. To contact AMO Pharma LTD, visit amo-pharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About AMO Pharma LTD

AMO Pharma LTD is a biopharmaceutical company founded in 2015 with a focus on developing innovative therapeutics for rare genetic neurodevelopmental disorders. Led by co-founder Dr. Michael Snape, who brings over twenty-five years of experience in senior scientific and operational roles in the pharmaceutical industry, the company has assembled a skilled management team with a strong track record in product development and acquisition. AMO Pharma is dedicated to advancing potential therapies for serious and debilitating diseases in patient populations with significant areas of unmet need, particularly rare, debilitating childhood onset neurogenetic disorders with limited or no current treatment options. Their lead investigational medicine, AMO-02, holds promise for addressing these unmet medical needs. The company received a $25.00M Private Equity Round investment from Woodford Patient Capital Trust in September 2015, demonstrating confidence from notable investors. With its commitment to addressing unmet medical needs, AMO Pharma is positioned to make a meaningful impact in the biotechnology, health care, and pharmaceutical industries. [For more information, please visit the AMO Pharma website at http://www.amo-pharma.com/.]

Taxonomy: Biopharmaceutical, Rare genetic disorders, Neurodevelopmental disorders, Clinical-stage pipeline assets, Rare muscular disorders, Central nervous system disorders, Rare diseases, Dr. Michael Snape, Pharma company, Clinical research, Senior management team, Product development, Acquisition, Patient populations, Unmet medical need

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Undisclosed 1
Acacia Research
09 Jan 2020
Private Equity Round $25.00M 1
Woodford Patient Capital Trust
Woodford Patient Capital Trust
30 Sep 2015

AMO Pharma LTD Alternatives & Competitors

View All Alternatives
AMO Pharma LTD vs
Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc. United States

A clinical-stage biopharmaceutical company focused on central nervous system disorders and rare dise...

Post-IPO Equity
8 employees
Biotechnology, Pharmaceutical
AMO Pharma LTD vs
Minerva Neurosciences
Minerva Neurosciences

Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on...

Post-IPO Equity
9 employees
Biopharma, Biotechnology
AMO Pharma LTD vs
Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. United States

The era of genetic neuroscience has arrived

IPO
244 employees
Biotechnology, Health Care
View all alternatives

FAQ About AMO Pharma LTD

AMO Pharma is working to develop novel therapeutics for rare genetic neurodevelopmental disorders
AMO Pharma LTD was founded in 2015.
AMO Pharma LTD is headquartered in Durham, United States.
AMO Pharma LTD operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Biopharmaceutical, Rare genetic disorders, Neurodevelopmental disorders and Clinical-stage pipeline assets.
AMO Pharma LTD has approximately 12 employees.
AMO Pharma LTD has completed 2 funding rounds, raising a total of $25.00M. The latest funding stage is Series A.
Top alternatives and competitors to AMO Pharma LTD include Seelos Therapeutics, Inc., Minerva Neurosciences, Praxis Precision Medicines, Inc., Epygenix Therapeutics, Inc., Ascendis Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AMO Pharma LTD and Seelos Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AMO Pharma LTD, https://bouncewatch.com/company/amo-pharma-ltd, updated 31 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes